Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Novavax seeks Covid-19 vaccine use in India ahead of US
The Novavax two-dose shot is made with lab-grown copies of the spike protein that coats the coronavirus. That's ["]very different["] than other widely used [mRNA] vaccines that deliver genetic instructions for the body to make its own spike protein.
In June [2021], Novavax announced the vaccine had proved about 90% effective against symptomatic Covid-19 in a study Phase III clinical trial of nearly 30,000 people in the U.S. and Mexico [and UK]. It also worked against variants circulating in those countries at the time. Side effects were mostly mild.
The Gaithersburg [Montgomery County], Maryland, company said it was on track to produce up to 100 million doses a month by the end of the third quarter and 150 million doses a month by year's end.
archived Tue Mar 3rd, 2020 "Johnson & Johnson [Janssen], Regeneron Pharmaceuticals Inc., Pfizer Inc. [BioNTech], Sanofi, GlaxoSmithKline PLC, Gilead Sciences Inc., Novavax Inc., Inovio Pharmaceuticals Inc., CureVac AG and Moderna Inc."
by Cat on Fri Aug 6th, 2021 at 04:04:35 PM EST
[ Parent ]
China to Begin Trials on Benefit of Mixing SinoVac, Inovio COVID-19 Vaccines This Autumn
Inovio CEO J. Joseph Kim said in a Monday press release
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA [!] Vaccine Candidate
the company's vaccine could serve as "a primary and a booster vaccine due to its tolerability, balanced cross-reactive immune responses, and strong thermostability profile that does not require cold or ultra-cold-chain transport."
< wipes tears >
According to IEEE Spectrum, Inovio's vaccine is delivered in a unique way: because traditional injection proved to have only limited effect, a special electroporation device delivers a small electric shock upon injection, which also uses a shorter needle. The minute shock opens channels into the recipient's cells temporarily, allowing the vaccine to be delivered.
"The success of the adenovirus-vectored AstraZeneca vaccine and mRNA vaccine by Pfizer-BioNTech combination may not be necessarily reproduced with other vaccine combinations," Julian Tang, a clinical virologist at Britain's University of Leicester, told the South China Morning Post, adding that scientists "need to try it and see."
by Cat on Wed Aug 11th, 2021 at 02:00:26 PM EST
[ Parent ]


Occasional Series